Then don't waste your time here. No one needs anyone to protect them from themselves. We have enough with gubberment. Speaking of which should be abolished.
The day will come where people ask me "how did you know all this"? I will reply. "Don't ask me that, ask yourself why you did not".
Recent FBIO News
- Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million • GlobeNewswire Inc. • 03/30/2026 08:05:00 PM
- Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/25/2026 08:01:00 PM
- Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher • IH Market News • 02/23/2026 03:43:08 PM
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million • GlobeNewswire Inc. • 02/23/2026 02:24:14 PM
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States • GlobeNewswire Inc. • 01/13/2026 12:45:00 PM
- Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission • GlobeNewswire Inc. • 12/15/2025 01:00:00 PM
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology • GlobeNewswire Inc. • 12/10/2025 01:30:00 PM
- Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/14/2025 01:30:00 PM
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/12/2025 09:01:00 PM
- Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics • GlobeNewswire Inc. • 11/06/2025 12:00:00 PM
- Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 • GlobeNewswire Inc. • 11/05/2025 01:30:00 PM
- Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference • GlobeNewswire Inc. • 10/24/2025 12:30:18 PM
- Fortress Biotech shares rise after Phase 3 launch of gout treatment • IH Market News • 10/21/2025 02:03:37 PM
- Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout • GlobeNewswire Inc. • 10/21/2025 12:30:37 PM
- Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO • PR Newswire (US) • 10/08/2025 09:45:00 PM
- Journey Medical Corporation to Participate in October 2025 Investor Conferences • GlobeNewswire Inc. • 10/08/2025 12:30:32 PM
- Fortress Biotech shares tumble after FDA rejection of Menkes treatment • IH Market News • 10/01/2025 02:19:46 PM
- Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing • GlobeNewswire Inc. • 10/01/2025 12:05:56 PM
- Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 • GlobeNewswire Inc. • 10/01/2025 12:00:46 PM
- Journey Medical Corporation to Participate in September 2025 Investor Conferences • GlobeNewswire Inc. • 09/03/2025 12:30:57 PM
